| Previous Close | 34.04 |
| Open | 34.13 |
| Bid | 33.98 x 10800 |
| Ask | 33.99 x 4700 |
| Day's Range | 33.84 - 34.07 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 6,189,418 |
| Avg. Volume | 21,532,439 |
| Market Cap | 202.85B |
| Beta | 1.06 |
| PE Ratio (TTM) | 28.61 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.75%) |
| Ex-Dividend Date | 2017-05-10 |
| 1y Target Est | N/A |
- Market Realist•2 hours ago
A Look at Pfizer’s Revenue for 1Q17
Pfizer (PFE) reported a 2.0% fall in 1Q17 revenues to ~$12.8 billion, with a 1.0% operational fall in revenues and a 1.0% negative impact of foreign exchange.
- Market Realist•3 hours ago
Pfizer’s Valuation as of June 22, 2017
Pfizer was trading at a forward PE multiple of ~12.8x on June 22, 2017, compared to the industry average of ~16.6x.
- Forbes•3 hours ago
Shocker: Merck Cholesterol Drug Yields Benefit Where Rivals Failed
Merck announced this morning that anacetrapib, a cholesterol-lowering medicine, reduced heart problems and strokes in a 30,000-patient clinical trial, giving the drug giant a success where Pfizer, Eli Lilly and Roche have all failed.
